Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration

Jonathan L. Haines, 1 Michael A. Hauser, 2 Silke Schmidt, 2 William K. Scott, 2 Lana M. Olson, 1 Paul Gallins, 2 Kylee L. Spencer, 1 Shu Ying Kwan, 2 Maher Nourreddine, 2 John R. Gilbert, 2 Nathalie Schnetz-Boutaud, 1 Anita Agarwal, 3 Eric A. Postel, 4 Margaret A. Pericak-Vance 2*

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD. We used single-nucleotide polymorphisms to interrogate this region and identified a strongly associated haplotype in two independent data sets. DNA resequencing of the complement factor H gene within this haplotype revealed a common coding variant, Y402H, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This common variant likely explains ~43% of AMD in older adults.

AMD causes progressive impairment of central vision and is the leading cause of irreversible vision loss in older Americans (1). The most severe form of AMD involves neovascular/exudative (wet) and/or atrophic (dry) changes to the macula. Although the etiology of AMD remains largely unknown,

1) with age at exam after age 64 (mean age at exam: 69.8 years). The six previously identified SNPs are DNA resequencing of the complement factor H gene within this haplotype revealed a common coding variant, Y402H, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This common variant likely explains ~43% of AMD in older adults.

Table 1. CFH sequence variants identified in neovascular AMD cases and normal controls. All individuals were homozygous for the AMD-associated GAGGT haplotype. The 24 affected individuals selected for sequencing had severe neovascular disease (grade 5) (12) with diagnosis before age 74 (mean age at diagnosis: 65.8 years). The 24 control individuals selected for sequencing had no evidence of AMD (grade 1) with age at exam after age 64 (mean age at exam: 69.8 years). The six previously identified SNPs are labeled using standard nomenclature. The five previously unknown variants are labeled given their base pair location on chromosome 1, Ensemble build 35. Five SNPs create nonsynonymous amino acid changes within CFH, and five SNPs create synonymous changes. Exon 1 is not translated. n/a, not applicable.

<table>
<thead>
<tr>
<th>Location</th>
<th>SNP ID</th>
<th>Effect</th>
<th>Minor allele frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Exon 1</td>
<td>rs3753394</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td>Exon 2</td>
<td>rs800292</td>
<td>V62I</td>
</tr>
<tr>
<td></td>
<td>Exon 6</td>
<td>193,380,486 A/G</td>
<td>R232R</td>
</tr>
<tr>
<td></td>
<td>Exon 7</td>
<td>rs1061147</td>
<td>A307A</td>
</tr>
<tr>
<td>Exon 8</td>
<td>193,390,164 C/T</td>
<td>H332Y</td>
<td></td>
</tr>
<tr>
<td>Exon 9</td>
<td>rs1061170</td>
<td>Y402H</td>
<td></td>
</tr>
<tr>
<td>Exon 11</td>
<td>193,414,604 A/G</td>
<td>A473A</td>
<td></td>
</tr>
<tr>
<td>Exon 12</td>
<td>193,416,415 A/G</td>
<td>T519A</td>
<td></td>
</tr>
<tr>
<td>Exon 14</td>
<td>rs3753396</td>
<td>Q672Q</td>
<td></td>
</tr>
<tr>
<td>Exon 18</td>
<td>193,438,299 C/T</td>
<td>H878H</td>
<td></td>
</tr>
<tr>
<td>Exon 19</td>
<td>HGVbase 000779895</td>
<td>E936D</td>
<td></td>
</tr>
</tbody>
</table>

www.sciencemag.org SCIENCE VOL 308 15 APRIL 2005
was identified as a likely region for an AMD risk gene, a location also supported by other studies (10, 11).

To identify the responsible gene on chromosome 1q32, we initially genotyped 44 single nucleotide polymorphisms (SNPs) across the 24 megabases (Mb) incorporating this linkage region. We examined two independent data sets: The first contained 182 families (111 multiplex and 71 discordant sibpairs), and the second contained 495 AMD cases and 185 controls. Each SNP was tested for association independently in both data sets. Two SNPs (rs2019724 and rs6428379) in moderate linkage disequilibrium with each other \( r^2 = 0.61 \) generated highly significant associations with AMD in both the family-based data set (rs2019724, \( P = 0.0001 \); rs6428379, \( P = 0.0007 \)) and in the case-control data set (rs2019724, \( P < 0.0001 \); rs6428379, \( P < 0.0001 \)). These SNPs lie \( \sim 263 \) kilobases (kb) apart.

To completely define the extent of linkage disequilibrium, we genotyped an additional 17 SNPs across \( \sim 655 \) kb flanked by rs1538687 and rs1537319 and encompassing the 263-kb region. Two linkage disequilibrium blocks of 11 and 74 kb were identified and were separated by 176 kb (Fig. 1). The 11-kb block contained rs2019724, and the 74-kb block contained rs6428379. Association analysis of the 17 SNPs identified multiple additional SNPs giving highly significant associations in one or both of the family-based and case-control data sets (Fig. 2). In the case-control data set, a five-SNP haplotype (GAGGT, defined by SNPs rs1831281, rs3753395, rs1853883, rs10494745, and rs6428279, respectively) constituted 46% of the case and 33% of the control chromosomes \( (P = 0.0003) \). This same haplotype was also significantly overtransmitted to affected individuals in the family-based data set \( (P = 0.00003) \). The convergence of the most significant associations to this same haplotype in the two independent data sets strongly suggests that this region contains a commonly inherited variant in an AMD risk gene.

The associated GAGGT haplotype spans \( \sim 261 \) kb. It contains the Complement Factor H gene \( (CFH, \text{OMIM #134370, accession #NM_000186}) \) and the five Complement Factor H–related genes \( \text{CFHL1 to CFHL5} \), and lies within the Regulator of Complement Activation (RCA) gene cluster. The most consistent association results (Fig. 2) from both the family-based and case-control data sets converge within the \( CFH \) gene, implicating \( CFH \) as the AMD susceptibility gene. The biological role of Complement Factor H as a component of the innate immune system that modulates inflammation through regulation of complement (13) enhances its attractiveness as a candidate AMD susceptibility gene. Inflammation has been repeatedly implicated in AMD pathology. C-reactive protein levels are elevated in advanced disease (14), antiretinal autoantibodies have been detected in AMD patients (15), macrophages are localized near neovascular lesions (16), and the hallmark drusen deposits contain many complement-related proteins (17).

We screened for potential risk-associated sequence variants in the coding region of \( CFH \) by sequencing 24 cases with severe neovascular disease and 24 controls with no evidence of AMD. We maximized the likelihood of identifying the risk-associated allele, all sequenced cases and controls were homozygous for the GAGGT haplotype. Five previously unknown and six known sequence variants were detected (Table 1). Only one variant (rs1061170, sequence: T1277C; protein: Y402H) was present significantly more often in cases than controls, occurring on 45 of 48 haplotypes in the cases and on 22 of 48 haplotypes in the controls.
haplotypes in the controls ($P < 0.0001$). The frequency of sequence variants within the CFH coding region on the associated haplotype was significantly reduced in cases compared to controls (12% versus 18%, $P = 0.002$). When the overrepresented T1277C variant was removed from the analysis, this difference became more pronounced (3% versus 16%, $P < 0.00001$). Thus, T1277C is the primary DNA sequence variant differentiating between the case and control haplotypes.

Complete genotyping of T1277C in the family-based and case-control data sets revealed a significant overtransmission in the families ($P = 0.019$) (12) and a highly significant overrepresentation in the cases compared to controls ($P = 0.00006$). The odds ratio for AMD was 2.45 [95% confidence interval (CI): 1.41 to 4.25] for carriers of one C allele and 3.33 (95% CI: 1.79 to 6.20) for carriers of two C alleles. When the analysis was restricted to only neovascular AMD, these odds ratios increased to 3.45 (95% CI: 1.72 to 6.92) and 5.57 (95% CI: 2.52 to 12.27), respectively. This apparent dose effect for risk associated with the C allele was highly significant ($P < 0.00001$). There was no apparent allelic or genotypic effect of T1277C on age at AMD diagnosis (mean age at diagnosis: TT, 76.5 years; TC, 77.5 years; CC, 75.5 years). The population attributable risk percent for carrying at least one C allele was 43% (95% CI: 23 to 68%).

The Y402H variant is predicted to have functional consequences consistent with AMD pathology. Residue 402 is located within heparin and CRP would alter CFH $\_2$ and C-reactive protein (CRP) (19). Binding to either of these partners increases the affinity of CFH for the complement protein C3b (20, 21), augmenting its ability to down-regulate complement’s effect. The observed colocalization of CFH, CRP, and proteoglycans in the superficial layer of the arterial intima suggests that CFH may protect the host arterial wall from excess complement activation (22). We hypothesize that allele-specific changes in the activities of the binding sites for heparin and CRP would alter CFH’s ability to suppress complement-related damage to arterial walls and might ultimately lead to vessel injury and subsequent neovascular/exudative changes such as those seen in neovascular AMD. Our data support this hypothesis, because the risk associated with the C allele is more pronounced when the analyses are restricted to neovascular AMD. Given the known functional interactions of genes within the RCA gene cluster (13), variants within these genes could interact with or modify the effect of the T1277C variant.

Plasma levels of CFH are known to decrease with smoking (23), a known risk factor for AMD (2). This confluence of genetic and environmental risk factors suggests an integrated etiological model of AMD involving chronic inflammation. Identification of the increased risk of AMD associated with the T1277C variant should enhance our ability to develop presymptomatic tests for AMD, possibly allowing earlier detection and better treatment of this debilitating disorder.

**References and Notes**

12. Materials and methods are available as supporting material on Science Online.
24. We thank all of the study participants and their relatives; M. de la Paz, M. Klein, J. Caldwell, R. Domurath, K. Haynes, V. Mitchell, M. Shaw, and J. Galloway for participant ascertainment; R. Abramson, J. Benton, W. Lambert, B. Love, T. Skelly, E. Tegnell, M. Allen, C. Haynes, R. Chung, and J. Bunch for valuable technical assistance; J. M. Vance and M. Summar for critical reading of the manuscript; and D. J. M. Gass for patient ascertainment and clinical expertise. We also thank the following clinics and clinicians for referring individuals to the study: Southern Retina, LLC (C. Harris); Vitreo-Retinal Surgeons (M. Duan and C. Devine); Georgia Retina, P.C.; and The Retina Group of Washington. Supported by grants EY12178 (to M.A.P.-V. and J.L.H.) and EY015216 (to S.S.) from the NIH/National Eye Institute, grant AG11268 from the NIH/National Institute on Aging (to H. Cohen), and grant M01 RR-00095 from the NIH/National Center for Research Resources (to Vanderbilt University).

Supporting Online Material

www.sciencemag.org/cgi/content/full/1110359/DC1
Materials and Methods
Table S1
References

28 January 2005; accepted 23 February 2005

Published online 10 March 2005; 10.1126/science.1110359

Include this information when citing this paper

---

**Complement Factor H Polymorphism and Age-Related Macular Degeneration**

**Albert O. Edwards,1,11 Robert Ritter III,1 Kenneth J. Abel,2 Alisa Manning,3 Carolien Panhuysen,3,6 Lindsay A. Farrer3,4,5,6,7**

Age-related macular degeneration (AMD) is a common, late-onset, and complex trait with multiple risk factors. Concentrating on a region harboring a locus for AMD on 1q25-31, the ARMD1 locus, we tested single-nucleotide polymorphisms for association with AMD in two independent case-control populations. Significant association ($P = 4.95 \times 10^{-10}$) was identified within the regulation of complement activation locus and was centered over a tyrosine-402 → histidine-402 protein polymorphism in the gene encoding complement factor H. Possession of at least one histidine at amino acid position 402 increased the risk of AMD 2.7-fold and may account for 50% of the attributable risk of AMD.

AMD is a leading cause of blindness in older individuals (1). It is a late-onset, complex trait with hereditary, lifestyle, and medical risk factors (2). The condition typically presents in the fifth decade of life with small yellow deposits external to the outer retina and retinal pigment epithelium (RPE) called drusen. Large numbers of drusen and clinical features of damage to the RPE markedly increase the risk of complications (atrophy of the RPE and abnormal neovascularization of the outer retina), leading to severe vision loss (1).

Although the primary pathogenic mechanisms of AMD were previously unknown, there is strong evidence that genetics plays a role (3–9). The first locus for AMD (ARMD1) was reported in a single extended family linked to chromosome 1q25.3-31.3 (5). Because there was strong evidence for linkage to this region